

zoetis



**DAPP<sup>+</sup>L4<sup>+</sup>CV**

**Injectable**

25 Vials (1 dose)

**CV LIQUID VACCINE**

25 Vials (1 mL)

# Canine Distemper- Adenovirus Type 2-Coronavirus- Parainfluenza-Parvovirus Vaccine

MODIFIED LIVE & KILLED VIRUS

## Leptospira Canicola- Grippotyphosa- Icterohaemorrhagiae- Pomona Bacterin

**To Reconstitute:**  
Rehydrate the vaccine  
with **CV liquid vaccine**  
for vaccination.

**VANGUARD<sup>®</sup>**



## DAPP+L4+CV Injectable

This product has been shown to be effective for the vaccination of healthy dogs 6 weeks of age or older against canine distemper virus (CDV), canine adenovirus type 1 (CAV1), canine adenovirus type 2 (CAV2), canine coronavirus (CCV), canine parainfluenza virus (CPIV), canine parvovirus (CPV), canine parvovirus type 2c (CPV2c), *Leptospira canicola*, *L. grippityphosa*, *L. icterohaemorrhagiae*, and *L. pomona*. Duration of immunity has not been established. For more information regarding efficacy and safety data, see [productdata.aphis.usda.gov](http://productdata.aphis.usda.gov).

Vanguard DAPP+L4+CV contains attenuated strains of CDV, CAV2, CPIV, CPV, inactivated CCV, and inactivated whole cultures of the four *Leptospira* serovars mentioned above. The high-titer, low-passage CPV virus in Vanguard DAPP+L4+CV is highly immunogenic and capable of stimulating active immunity in the presence of maternal antibodies. This product does not contain CPV type 2c. Cross protection against CPV type 2c was demonstrated in vaccinated puppies challenged 5 weeks following second vaccination.

Vaccination and revaccination according to label directions have been demonstrated (under field conditions) to result in serum antibody titers that persist for 12–48 months against CDV (serum neutralization [SN] titer  $\geq 1:32$ ), CAV1 (SN  $\geq 1:16$ ), CAV2 (SN  $\geq 1:16$ ), CPIV (SN  $\geq 1:16$ ), and CPV (hemagglutination inhibition [HAI] titer  $\geq 1:80$ ).

**Directions:** Aseptically rehydrate the freeze-dried vaccine with the accompanying vial of adjuvanted liquid vaccine, shake well, and administer 1 mL subcutaneously or intramuscularly. Healthy dogs should receive 2 doses administered 3 weeks apart, followed by a single dose of Vanguard Canine CV 3 weeks later. The presence of maternal antibody is known to interfere with the development of active immunity in puppies and additional boosters will be required in most young animals. Historically, annual revaccination with this product was recommended. The need for annual booster vaccinations has not been established. For advice on revaccination, consult your veterinarian or the manufacturer.

**Precautions:** Store upright at 2°–8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Inactivate unused contents before disposal. Contains gentamicin and thimerosal as preservatives. This product has not been tested in pregnant animals. In case of anaphylactoid reaction, administer epinephrine. Do not mix with other products, except as specified above. In case of human exposure, contact a physician.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

40033831